Blog
RSS FeedPosted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 20 Jan 2022
NICE moves: increased accessibility and flexibility for health tech
19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...
Posted by Michael Wonder on 20 Jan 2022
NICE signals commitment to greater flexibility in its evaluation of promising new health technologies and making patient access fairer
20 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE for use in the ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 11 Jan 2022
NICE recommends Rinvoq for psoriatic arthritis patients
10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending ...
Posted by Michael Wonder on 07 Jan 2022
NICE recommends MSD’s Keytruda in combination with chemotherapy for routine treatment of lung cancer
7 January 2022 - With over 48,000 new cases diagnosed per year, lung cancer is the third most common cancer ...
Posted by Michael Wonder on 26 Dec 2021
Children and young people set to benefit from new treatment for peanut allergy
23 December 2021 - Children and young people aged between 4 and 17 with a peanut allergy could be set to ...
Posted by Michael Wonder on 20 Dec 2021
NICE recommends monotherapy for adjuvant treatment of stage 3 melanoma
17 December 2021 - The approval follows a successful period of monitoring and patient access through the Cancer Drugs Fund. ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommend venetoclax and azacitidine for patients with aggressive blood cancer
16 December 2021 - Venetoclax is an oral once daily treatment, which blocks the action of the B-cell lymphoma-2 protein, ...
Posted by Michael Wonder on 16 Dec 2021
NICE recommends offering PrEP to people at high risk of HIV for first time
15 December 2021 - People at the highest risk of catching HIV should be offered pre-exposure prophylaxis, NICE has recommended for ...
Posted by Michael Wonder on 15 Dec 2021
NICE finally accepts use of rare cancer therapy Poteligeo
15 December 2021 - NICE has reversed its earlier decision not to recommend the use of Kyowa Kirin’s Poteligeo (mogamulizumab). ...
Posted by Michael Wonder on 09 Dec 2021
NICE publish final guidance recommending Aspaveli in adults with ultra rare blood disorder
9 December 2021 - The medicine is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a ...
Posted by Michael Wonder on 08 Dec 2021
NICE terminates appraisal of yet another cancer medicine
7 December 2021 - NICE is unable to make a recommendation on the use of olaparib (Lynparza) on the NHS for ...
Posted by Michael Wonder on 01 Dec 2021
NICE terminates appraisal of new treatment for adolescents with obesity
1 December 2021 - NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in adolescents aged 12 ...
Posted by Michael Wonder on 29 Nov 2021
NICE publishes draft guidance on new medicine for osteoporosis
25 November 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using romosozumab in ...